BENICAR: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Cosette	BENICAR	olmesartan medoxomil	TABLET;ORAL	021286	NDA	Cosette Pharmaceuticals, Inc.	0713-0860-30	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0713-0860-30)	2022-09-01
Cosette	BENICAR	olmesartan medoxomil	TABLET;ORAL	021286	NDA	Cosette Pharmaceuticals, Inc.	0713-0861-30	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0713-0861-30)	2022-09-01
Cosette	BENICAR	olmesartan medoxomil	TABLET;ORAL	021286	NDA	Cosette Pharmaceuticals, Inc.	0713-0862-30	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0713-0862-30)	2022-09-01
Cosette	BENICAR	olmesartan medoxomil	TABLET;ORAL	021286	NDA	Cosette Pharmaceuticals, Inc.	0713-0940-30	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0713-0940-30)	2025-08-01
Cosette	BENICAR	olmesartan medoxomil	TABLET;ORAL	021286	NDA	Cosette Pharmaceuticals, Inc.	0713-0941-30	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0713-0941-30)	2025-08-01
Cosette	BENICAR	olmesartan medoxomil	TABLET;ORAL	021286	NDA	Cosette Pharmaceuticals, Inc.	0713-0942-30	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0713-0942-30)	2025-08-01
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Benicar (olmesartan medoxomil), a widely prescribed angiotensin II receptor blocker (ARB) used to treat hypertension, relies on a complex global supply chain for its active pharmaceutical ingredient (API). The market for olmesartan medoxomil API is characterized by established manufacturers, evolving regulatory landscapes, and strategic importance for generic drug producers. This analysis details key suppliers and the market dynamics impacting their operations.

What is the Global Market Size for Olmesartan Medoxomil API?

The global market for olmesartan medoxomil API is substantial, driven by the continued prevalence of cardiovascular diseases and the availability of generic formulations. While precise, up-to-the-minute market size figures are proprietary and fluctuate, industry estimates place the market in the hundreds of millions of U.S. dollars annually. The demand is sustained by both branded and generic Benicar, with generic competition intensifying following patent expirations in major markets. The growth trajectory is influenced by factors such as aging populations, increased awareness of hypertension management, and the expansion of healthcare access in emerging economies.

Who are the Primary Manufacturers of Olmesartan Medoxomil API?

The production of olmesartan medoxomil API is concentrated among a select group of global pharmaceutical chemical manufacturers. These companies possess the specialized expertise, manufacturing capacity, and regulatory compliance necessary for API synthesis. Key players include:

Daiichi Sankyo Co., Ltd.: As the originator of Benicar, Daiichi Sankyo is a primary producer of olmesartan medoxomil API, particularly for its branded product and potentially for strategic partnerships.
Dr. Reddy's Laboratories: A major Indian pharmaceutical company with significant API manufacturing capabilities, Dr. Reddy's is a known supplier of olmesartan medoxomil API to the generic market.
Lupin Ltd.: Another prominent Indian pharmaceutical firm, Lupin has a strong presence in the generic API sector and is a supplier of olmesartan medoxomil medoxomil API.
Sun Pharmaceutical Industries Ltd.: Sun Pharma, a global pharmaceutical giant, also participates in the olmesartan medoxomil API market, leveraging its extensive manufacturing network.
Aurobindo Pharma Limited: Aurobindo is recognized for its broad portfolio of generic APIs and is a significant producer of olmesartan medoxomil API.
Hetero Drugs Limited: A leading Indian generic pharmaceutical company, Hetero manufactures and supplies olmesartan medoxomil API to global markets.
Cipla Ltd.: Cipla is a well-established player in the pharmaceutical API space, including the production of olmesartan medoxomil API.
Gland Pharma Limited: While often recognized for finished dosage forms, Gland Pharma also has API manufacturing capabilities and can be a supplier in this segment.
Zhejiang Huahai Pharmaceutical Co., Ltd.: A significant Chinese pharmaceutical manufacturer, Huahai is a major global supplier of APIs, including olmesartan medoxomil medoxomil.
Qilu Pharmaceutical Co., Ltd.: Another major Chinese API producer, Qilu Pharmaceutical contributes to the global supply of olmesartan medoxomil API.

These manufacturers operate under stringent Good Manufacturing Practice (GMP) regulations enforced by bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

What are the Key Manufacturing Processes and Raw Materials for Olmesartan Medoxomil API?

The synthesis of olmesartan medoxomil API involves a multi-step chemical process, typically starting from basic chemical intermediates. While the exact proprietary routes may vary between manufacturers, common synthetic pathways utilize key starting materials and intermediates.

General Synthetic Pathway Components:

The synthesis generally involves the coupling of an imidazole derivative with a biphenyl tetrazole moiety, followed by esterification to form the medoxomil ester.

Key Intermediates and Precursors:
- 5-substituted-1H-tetrazoles (e.g., a cyanobiphenyl derivative).
- Imidazolyl derivatives (e.g., 2-butyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-4-carboxylic acid ethyl ester).
- Medoxomil chloride or similar activating agents for esterification.
Critical Raw Materials:
- Biphenyl derivatives: These are foundational for the biphenyl tetrazole structure.
- Imidazole precursors: Essential for forming the imidazole ring.
- Reagents for cyclization and coupling: Including catalysts and solvents.
- Esterification agents: Such as chloromethyl isopropyl carbonate or related compounds to introduce the medoxomil ester group.
- Solvents: A variety of organic solvents are used throughout the synthesis, requiring careful management for purity and recovery.
- Catalysts: Various catalysts are employed to facilitate specific reaction steps.

The manufacturing process requires precise control over reaction conditions, temperature, pressure, and reagent stoichiometry to ensure high yield and purity of the final API. Impurity profiling and control are critical to meet regulatory standards.

What are the Regulatory Considerations for Olmesartan Medoxomil API Suppliers?

Suppliers of olmesartan medoxomil API must adhere to a rigorous regulatory framework to ensure product quality, safety, and efficacy. This framework is overseen by national and international health authorities.

Good Manufacturing Practices (GMP): Compliance with GMP guidelines, as stipulated by regulatory bodies such as the FDA (21 CFR Parts 210 and 211), EMA (EudraLex Volume 4), and other national agencies, is mandatory. This encompasses facility design, equipment qualification, process validation, quality control, and personnel training.
Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory authorities. A DMF provides confidential, detailed information about the facilities, processes, and materials used in the manufacturing, processing, packaging, and storing of the API. Pharmaceutical companies seeking to use the API in their drug products reference these DMFs in their marketing authorization applications.
Impurity Control: Regulatory agencies place significant emphasis on controlling impurities, particularly genotoxic impurities. The presence of N-nitroso-olmesartan medoxomil has been a notable concern, leading to recalls and heightened scrutiny of manufacturing processes and analytical testing methods. Manufacturers must demonstrate robust control strategies to limit such impurities to acceptable levels, often defined by ICH guidelines (e.g., ICH M7).
Site Inspections and Audits: API manufacturing sites are subject to regular inspections by regulatory authorities and audits by their pharmaceutical clients. These inspections verify compliance with GMP and other relevant regulations.
Certificate of Suitability (CEP): For APIs intended for the European market, manufacturers can obtain a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM). This demonstrates that the API complies with the relevant European Pharmacopoeia monograph.
ICH Guidelines: Adherence to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines (e.g., ICH Q7 for API GMP, ICH Q3A/B/C/D for impurities) is crucial for global market access.

What is the Impact of Patent Expirations and Generic Competition?

The patent landscape significantly influences the market for olmesartan medoxomil API. The expiration of key patents for Benicar has opened the door for widespread generic competition.

Loss of Exclusivity: Once the primary patents protecting olmesartan medoxomil medoxomil expire, generic manufacturers can enter the market, leading to a decrease in the price of the finished drug product.
Increased API Demand from Generic Manufacturers: This surge in generic drug production directly translates to increased demand for olmesartan medoxomil API from generic API suppliers.
Price Pressures on API Manufacturers: While demand increases, the heightened competition among generic drug makers also exerts downward price pressure on the API itself. API suppliers must achieve manufacturing efficiencies to remain competitive.
Supply Chain Diversification: Pharmaceutical companies developing generic Benicar formulations often seek to diversify their API suppliers to mitigate risk, ensure continuity of supply, and negotiate favorable pricing.
Quality and Regulatory Compliance as Differentiators: In a competitive generic market, the quality, reliability, and regulatory compliance of an API supplier become critical differentiating factors. Companies with a strong track record and robust quality systems are preferred.

How Do Supply Chain Disruptions Affect Benicar API Sourcing?

The global nature of API manufacturing makes the supply chain susceptible to various disruptions, impacting the availability and cost of olmesartan medoxomil API.

Geopolitical Instability: Events in major API manufacturing regions (e.g., India, China) can disrupt production and export.
Natural Disasters and Pandemics: Events like earthquakes, floods, or global health crises (e.g., COVID-19) can halt manufacturing operations, impede logistics, and strain raw material availability.
Regulatory Changes and Enforcement: Stricter environmental regulations in API manufacturing countries can lead to temporary or permanent plant closures. Increased regulatory scrutiny and enforcement actions (e.g., warning letters, import alerts) against specific manufacturing sites can disrupt supply.
Raw Material Shortages and Price Volatility: Fluctuations in the availability and cost of key starting materials and intermediates can directly affect API production costs and lead times.
Logistics and Transportation Issues: Port congestion, shipping container shortages, and increased freight costs can delay deliveries and add to overall supply chain expenses.
Quality Control Failures: Adverse findings during quality control testing or regulatory inspections can lead to batch rejections, recalls, and temporary cessation of manufacturing, creating immediate supply gaps.

Pharmaceutical companies relying on olmesartan medoxomil API must implement robust supply chain risk management strategies, including dual sourcing, maintaining safety stocks, and close collaboration with suppliers to monitor potential disruptions.

What are the Future Trends in Olmesartan Medoxomil API Supply?

The market for olmesartan medoxomil API is expected to evolve with ongoing trends in pharmaceutical manufacturing and regulation.

Increased Focus on Supply Chain Resilience: Companies will continue to invest in diversifying their supplier base, potentially exploring regional manufacturing hubs to reduce reliance on single geographies.
Advancements in Manufacturing Technology: The adoption of continuous manufacturing and process analytical technology (PAT) could improve efficiency, reduce waste, and enhance quality control in API production.
Stricter Impurity Control: Regulatory agencies are likely to maintain or increase scrutiny on impurity profiles, particularly genotoxic impurities, driving further investment in advanced analytical techniques and process optimization by API manufacturers.
Sustainability in Manufacturing: Environmental considerations are becoming more prominent. API suppliers may face increasing pressure to adopt greener chemistry principles, reduce solvent usage, and improve energy efficiency.
Consolidation in the API Sector: Market dynamics may lead to consolidation among API manufacturers, with larger, well-capitalized companies acquiring smaller players to enhance their market share and technological capabilities.
Data Integrity and Digitalization: Enhanced focus on data integrity in manufacturing processes, coupled with increased digitalization of supply chain management and quality systems, will be a significant trend.

Key Takeaways

The olmesartan medoxomil API market is a dynamic segment of the pharmaceutical industry, primarily driven by generic demand following patent expirations. Key manufacturers are concentrated in India and China, alongside originator companies. Regulatory compliance, particularly concerning Good Manufacturing Practices and impurity control, is paramount. Supply chain resilience, influenced by geopolitical factors, quality control, and raw material availability, remains a critical consideration for sourcing. Future trends indicate a focus on supply chain diversification, advanced manufacturing technologies, and stringent impurity management.

Frequently Asked Questions

What is the typical lead time for ordering olmesartan medoxomil API?

Typical lead times for olmesartan medoxomil API can range from 8 to 16 weeks, depending on the manufacturer's current production schedule, order volume, and specific contractual agreements. This does not include time for shipping and customs clearance.

How does the FDA's scrutiny of N-nitroso-olmesartan medoxomil affect suppliers?

The FDA's scrutiny of N-nitroso-olmesartan medoxomil has led to increased analytical testing requirements, process validation reviews, and potential batch rejections or recalls for affected suppliers. Manufacturers must demonstrate robust control strategies to mitigate these nitrosamine impurities to meet acceptable intake levels.

Are there regional preferences for sourcing olmesartan medoxomil API?

While API manufacturers are globally distributed, there is a significant concentration of suppliers in India and China due to cost advantages and established manufacturing infrastructure. However, companies in North America and Europe also produce API, often for domestic markets or specialized needs, and regulatory compliance is generally higher.

What are the primary risks associated with relying on a single supplier for olmesartan medoxomil API?

Relying on a single supplier for olmesartan medoxomil API carries significant risks, including potential supply chain disruptions due to manufacturing issues, quality failures, geopolitical events, or regulatory actions. This single point of failure can lead to drug shortages and impact patient access to medication.

How do API manufacturers ensure the quality and purity of olmesartan medoxomil medoxomil?

API manufacturers employ a multi-faceted approach to ensure quality and purity. This includes rigorous raw material testing, in-process controls, validated analytical methods for final product testing (e.g., HPLC, GC-MS), impurity profiling, stability studies, and adherence to strict GMP guidelines throughout the manufacturing process.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) Regulations. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/drugs/pharmaceutical-manufacturing/current-good-manufacturing-practice-cgmp-regulations

[2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. European Medicines Agency. Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/eudralex

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. ICH. Retrieved from https://www.ich.org/page/guidelines

[4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). EDQM. Retrieved from https://www.edqm.eu/en/certificate-suitability-monographs-european-pharmacopoeia-cep

[5] Daiichi Sankyo Company, Limited. (n.d.). Company Information. Retrieved from https://www.daiichisankyo.com/

[6] Dr. Reddy's Laboratories. (n.d.). API Business. Retrieved from https://www.drreddys.com/businesses/api-business/

[7] Lupin Limited. (n.d.). API Business. Retrieved from https://www.lupin.com/business-segments/api-business/

[8] Sun Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from https://www.sunpharma.com/business/api-manufacturing

[9] Aurobindo Pharma Limited. (n.d.). API Products. Retrieved from https://www.aurobindo.com/products/api-products

[10] Hetero Drugs Limited. (n.d.). API Division. Retrieved from https://www.heterodrugs.com/api-division

[11] Cipla Ltd. (n.d.). API Manufacturing. Retrieved from https://www.cipla.com/business-segments/api-manufacturing

[12] Gland Pharma Limited. (n.d.). API Business. Retrieved from https://www.glandpharma.com/api-business

[13] Zhejiang Huahai Pharmaceutical Co., Ltd. (n.d.). API Business. Retrieved from https://www.huahaipharm.com/API-Business/

[14] Qilu Pharmaceutical Co., Ltd. (n.d.). API Manufacturing. Retrieved from https://www.qilu-pharma.com/API-Manufacturing

Suppliers and packagers for BENICAR

BENICAR

Benicar API Suppliers and Market Landscape